WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 1319

Legislative bill overview

HB 1319 would authorize Texas to establish a program allowing wholesale importation of prescription drugs from other states or countries where they are approved and sold at lower prices. This represents a state-level response to high drug costs by creating a legal pathway for purchasing medications outside traditional pharmaceutical supply chains.

Why is this important

Prescription drug costs remain a significant burden for many Texans, with some medications costing substantially more domestically than in other developed nations. If implemented, this could reduce out-of-pocket expenses for patients and potentially lower overall healthcare costs, though it also introduces regulatory and safety considerations into drug sourcing.

Potential points of contention

  • Federal regulatory conflict: The federal Food and Drug Administration (FDA) has traditionally opposed state drug importation programs, arguing they violate federal law and complicate drug safety oversight, creating potential legal challenges.
  • Pharmaceutical industry opposition: Drug manufacturers may argue that importation undermines pricing structures, reduces profit margins, and could discourage domestic pharmaceutical innovation and research.
  • Supply chain safety and authenticity: Importing drugs from multiple sources raises questions about verifying drug authenticity, preventing counterfeit medications, maintaining proper storage conditions, and ensuring consistent quality standards across different regulatory systems.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.